Health Canada has published a new Ministerial Reliance Order, giving the department a formal pathway to speed up select drug reviews by relying on decisions or documents already produced by trusted foreign regulators. Announced July 15, 2026, the Order is part of a broader effort to modernize Health Canada’s regulatory review process while maintaining the department’s existing standards for safety, efficacy, and quality.
The first classes of drugs eligible under the Order are drugs for pediatric use and veterinary drugs. Companies working in either category should take note, since this is a meaningful shift in how those submissions may be reviewed going forward.
What the Order Does
Rather than requiring Health Canada to independently reproduce every element of a foreign regulator’s assessment, the Order permits reviewers to draw on select decisions or documents already produced elsewhere. Health Canada retains its own review authority and its own standards; the Order is intended to remove unnecessary duplication, not to replace Canadian review altogether.
According to the Minister of Health, the Honourable Marjorie Michel, the goal is straightforward: Canadians expect timely access to safe and effective treatments without unnecessary delays, and this is one part of reducing that duplication.
Companies can review the full details of the Order directly through Health Canada.
Why Pediatric and Veterinary Drugs First
The choice to start with these two categories is not incidental. As Emily Gruenwoldt, President and CEO of Children’s Healthcare Canada and Executive Director of the Pediatric Chairs of Canada, noted, pediatric drug development has long been slowed by small patient populations and limited commercial incentive, which makes regulatory efficiency especially valuable in that space.
Veterinary drugs face a related challenge: smaller markets relative to human drugs, which can mean longer waits for review resources. Including both categories in the initial rollout signals where Health Canada sees the most immediate benefit.
A Second, Related Development
Alongside the Reliance Order, Health Canada is separately seeking feedback on a proposed approach to prioritize the review of certain generic drug submissions involving Canadian manufacturing. This is a distinct initiative aimed at supporting Canada’s generic pharmaceutical and life sciences sector and strengthening the security of the domestic drug supply.
Both this proposal and the draft guidance for the Reliance Order itself are open for public consultation from July 15 to September 12, 2026.
Context: A Broader Modernization Push
This Order arrives alongside other signs of momentum at Health Canada. Over the past three months, the department approved 537 new drugs and medical devices, including three generic versions of semaglutide — making Canada the first G7 country to authorize a generic version of the drug. Dr. Bettina Hamelin, President and CEO of Innovative Medicines Canada, pointed to the current trade environment as a reason the Order’s implementation carries added weight for Canada’s standing as a launch destination for new treatments.
What This Means for Your Business
Companies with pediatric or veterinary drug submissions in progress, or under consideration for the Canadian market, should review whether their product may qualify under the new Order. Since Health Canada has not yet published specific target review timelines or a list of recognized foreign authorities, companies should treat this as an emerging pathway rather than a guaranteed shortcut, and watch for further guidance as the consultation period progresses.
Companies manufacturing generic drugs domestically should also track the separate consultation on prioritized review, since it may affect submission strategy independently of the Reliance Order.
Quality Smart Solutions supports companies preparing pediatric, veterinary, and generic drug submissions in Canada, and can help assess how these developments may affect a company’s submission timeline as more detail becomes available.
Frequently Asked Questions
Does the Ministerial Reliance Order mean foreign drug approvals are automatically accepted in Canada?
No. The Order allows Health Canada to use select foreign regulatory decisions or documents to review certain parts of a submission more efficiently. It does not create automatic recognition, and Health Canada retains its own review authority and standards.
Which drug categories are covered right now?
The first classes confirmed under the Order are drugs for pediatric use and veterinary drugs. Health Canada has not indicated when or whether other categories will be added.
Is this the same as the generic drug manufacturing proposal?
No. These are two separate initiatives announced at the same time. The Reliance Order addresses pediatric and veterinary drug reviews; the generic drug proposal is a distinct consultation focused on prioritizing submissions tied to Canadian manufacturing.
Key Takeaways
- Health Canada’s new Ministerial Reliance Order, announced July 15, 2026, lets the department use select foreign regulatory decisions to review certain submission elements faster.
- The first eligible classes are pediatric drugs and veterinary drugs — not drug submissions broadly.
- A separate consultation on prioritizing generic drug submissions tied to Canadian manufacturing is open at the same time.
- Both consultations run from July 15 to September 12, 2026.
- No specific timelines or list of recognized foreign authorities have been published yet.
Looking Ahead
As Health Canada finalizes guidance and potentially expands the Ministerial Reliance Order’s scope, companies with pediatric or veterinary drug submissions have a clear reason to pay attention now. Building a submission strategy around an evolving pathway takes regulatory judgment, not just awareness of the announcement.
Quality Smart Solutions supports companies through Canadian OTC drug compliance and veterinary health product licensing, and can help assess whether a specific submission may benefit from the new Order as further guidance is published.
If your company has a pediatric or veterinary drug submission in progress or on the horizon for the Canadian market, contact us to talk through how this development may affect your timeline.
